熙源安健

Xiyuan Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for pain management and inflammatory diseases. Headquartered in Suzhou, China, the company leverages its proprietary platform to target ion channels and G protein-coupled receptors (GPCRs) involved in pain signaling. Its lead program, XY0206, is a selective Nav1.8 inhibitor designed to provide a non-opioid alternative for the treatment of acute and chronic pain. The company's pipeline also includes candidates targeting Nav1.7 and TrkA for indications such as neuropathic pain and osteoarthritis. Xiyuan Biotech aims to address significant unmet medical needs by providing safer and more effective analgesic options. The firm is supported by leading venture capital investors, including Sequoia China and Hillhouse Capital.